Harnessing salinity gradient energy: Pushing forward in water reclamation via on-site reverse electrodialysis technology.

Effluents from urban wastewater treatment plants (UWWTPs) discharged into water bodies such as the sea or ocean, offer a potential source of renewable energy through the salinity gradient (SGE) between seawater and treated water. The European project Life-3E: Environment-Energy-Economy aims to demonstrate an innovative process integrating renewable energy production with water reclamation. Using reverse electrodialysis (RED) technology, SGE can power tertiary wastewater treatment processes in coastal UWWTPs, offsetting energy costs associated with water regeneration and reuse.

Cost-effectiveness analysis of dupilumab versus omalizumab, mepolizumab, and benralizumab added to the standard of care in adults with severe asthma in Colombia.

Background: Cost-effectiveness studies evaluate health technologies and help choose treatments. The current study compared dupilumab to omalizumab, mepolizumab, and benralizumab in Colombian adults with severe uncontrolled type 2 asthma.

Methods: Over a 5-year period, a Markov model was utilized to assess the costs of biological treatments and management of exacerbations, comparing various doses of exacerbations, comparing various doses of dupilumab, omalizumab, mepolizumab, and benralizumab as add-on treatments.

Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.

In a multicenter European retrospective study including 162 patients with COVID-19 occurring in essential thrombocythemia (ET, n = 48), polycythemia vera (PV, n = 42), myelofibrosis (MF, n = 56), and prefibrotic myelofibrosis (pre-PMF, n = 16), 15 major thromboses (3 arterial and 12 venous) were registered in 14 patients, of whom all, but one, were receiving LMW-heparin prophylaxis. After adjustment for the competing risk of death, the cumulative incidence of arterial and venous thromboembolic events (VTE) reached 8.5% after 60 days follow-up.

Management of Intraoperative Crisis During Nonintubated Thoracic Surgery.

Nonintubated video-assisted thoracoscopic surgery programs have gradually spread all over the world. The benefits are based on less invasiveness and earlier recovery. However, complications may appear.

Regionalization of housing policies? An exploratory study of Andalusia, Catalonia and the Basque Country.

The Spanish home ownership sector has been hit hard by the economic crisis. Repossessions stand at around half a million in the period from 2008 to 2014. This article investigates how the authorities, both at the level of the Spanish state and of the autonomous communities (regions), have responded to this problem.

[Results of three-year clinical study of prostamol uno efficacy and safety in patients with initial symptoms of prostatic adenoma and risk of its progression].

Prostamol Uno (PU) efficacy and safety were studied in a multicenter, open-population, randomized and comparative trial. PU was given in a single daily dose 320 mg for 36 months to 50 patients with initial symptoms of prostatic adenoma (PA) in comparison with 50 matched controls. The trial evaluated PU action on the symptoms progression and quality of life with application of questionnaires IPSS and QoL (BS).

Prophylactics of erectile dysfunction in patients with metabolic syndrome.

For prophylactics of erectile dysfunction in patients with metabolic syndrome, all unfavorable life-style factors should be excluded and all metabolic disturbances should be corrected. This will reduce the severity and stabilize the course of metabolic syndrome. Administration of special drugs is required for prevention of erection disturbances.

[Efficacy and safety of prostamol-UNO in the treatment of patients with initial symptoms of prostatic adenoma and risk of progression: 2 years of investigations].

The article presents 2-year pilot results of a multicenter, randomized, controlled trial of prostamol-UNO effects on symptoms progression, quality of life, tolerance and safety in patients with early prostatic adenoma. The drug was used in a single dose 320 mg/day for 36 months. Prostamol-UNO efficacy in arrest of the symptoms progression and quality of life was assessed with the use of IPSS and QoL (BS) questionnaires.

[Vitaprost plus in the treatment of chronic bacterial prostatitis].

Our study has demonstrated that compound medicine vitaprost plus in therapy of chronic bacterial prostatitis (CBP) reduces intensity of prostatic inflammation, significantly relieves symptoms of chronic prostatitis and pain syndrome. The absence of unwanted side effects, significant changes in clinical and biochemical blood and urine parameters evidences for good tolerance and safety of the drug. Thus, rectal suppositories vitaprost plus can be recommended for treatment of chronic bacterial prostatitis caused by both gram-positive and gram-negative bacteria in patients of different age and clinical symptoms.

[Efficacy of phosphodiesterase inhibitors in the treatment of patients with organic erectile dysfunction: a comparative study].

Currently available three highly selective and effective PDE-5 inhibitors (sildenafil, tadalafil and wardenafil) are comparable by PDE-5 inhibition and selectivity of action on PDE-5 but their differences in activity, interaction with food and alcohol, biological half-life and other characteristics make their use individual for certain clinical situations. Our trial with participation of 575 patients (mean age 57.73 +/- 12.

[Administration of oral vitaprost for prevention of exacerbations of chronic abacterial prostatitis].

Active substance of vitaprost is a complex of water-soluble biologically active peptides isolated from bovine prostate. The prostatic extract has an organotropic action in relation to the prostate. As all peptide bioregulators, prostatic extract has antiaggregant and anticoagulant properties, enhances synthesis of antihistamine and antiserotonine antibodies, improves microcirculation in the prostatic gland.

[Temporary stent--CoreFlow Soft Stent--for diagnosis of the causes of incomplete bladder emptying in men with neurological diseases].

The new device--CoreFlow Soft Stent--was used for diagnosis of causes of incomplete bladder emptying (IBE) in 19 men with neurogenic diseases. Group 1 consisted of 8 men with IBE and prostatic adenoma. Group 2 consisted of 11 men with IBE but no prostatic adenoma.

[Effects of different treatments on endothelial function in patients with erectile dysfunction and hypogonadism].

Aim: To study effects of different treatments on erectile and endothelial functions in patients with erectile dysfunction (ED) and age-related hypogonadism (HG).

Material And Methods: The study included 66 males with ED who had clinical and laboratory signs of HG. All the patients were examined using questionnaires (international index of erectile function, AMS), blood hormones tests.

[Botulinum A toxin in the treatment of patients with detrusor external sphincter dyssynergia and neurogenic low detrusor contractility].

Aim: To investigate safety and efficacy of botulinum A toxin external urethral sphincter injection in the treatment of patients with detrusor external sphincter dyssynergia (DSD) and neurogenic low detrusor contractility (DC).

Material And Methods: The study included 21 patients with DSD and 27 patients with low DC between 17 and 73 years of age. The diagnostic scheme consisted of voiding diary for 72 hours, laboratory tests, ultrasound investigation with measurement of residual urine volume, urodynamic investigation and neurologic examination.

[Levitra (wardenafil) effects on endothelial function of brachial and cavernous arteries].

We studied effects of oral PDE-5 inhibitor wardenafil (levitra, Bayer & GlaxoSmithKline) on endothelial function of cavernous and brachial arteries in males with normal erectile function and in patients with erectile dysfunction (ED). Endothelial function of the brachial and cavernous arteries was studied in 75 males with ED and 20 healthy volunteers before and after wardenafil intake in a dose 20 mg using ultrasound examination of postcompression diameter changes. The results show that wardenafil improves endothelial function of cavernous and brachial arteries.

[Trospium chloride in combined treatment of females with genital prolapse and overactive urinary bladder].

The trial of efficacy of trospium chloride (TC) in a dose of 45 mg/day in females with overactive bladder (OAB) symptoms preserved after genital prolapse (GP) surgical correction included 28 females (age 55-82, mean age 68.07 +/- 12 years). GP was corrected by means of vaginal hysterectomy and anterior colporraphy.

Study of the correlation between clinical efficiency of impaza and serum ADMA level.

Correlation between superlow-dose antibodies to endothelial NO synthase (Impaza) and serum level of ADMA was evaluated in a double blind placebo-controlled study. The reduction of ADMA in patients with erectile dysfunction after impaza treatment was paralleled by improvement of clinical symptoms. No clear-cut correlation between ADMA level and impaza effect was detected.

[Etiotropic therapy of chronic bacterial prostatitis].

A total of 20 patients entered the clinical trial of efficacy and safety of Russian produced drug levofloxacin (floracid) in the treatment of chronic bacterial prostatitis (CBP). The drug was given in a single dose of 500 mg/day for 28 days. Antibacterial treatment of CBP with floracid killed sensitive to it bacteria in 18 of 20 (90%) CBP patients.

[Efficacy and safety of a new dosage form of vitaprost (tablets coated with intestinally soluble cover) in patients with prostatic adenoma].

An active substance of the drug vitaprost is a complex of water-soluble biologically active peptides isolated from bovine prostatic gland. The prostatic extract has an organ-tropic action in relation to the prostate: inhibits proliferative activity of the cells leading to suppression of prostatic adenoma development, reduces edema and activity of inflammation in prostatic diseases. The new vitaprost tablets can decrease volume of the prostate (this trend was not significant), relieve infravesical obstruction and irritation, improve quality of life.